Pharma split: The Tipline for 18 November 2019
We had a split decision at the Federal Trade Commission. The agency voted 3-2 to order drugmakers Bristol-Myers Squibb and Celgene divest psoriasis drug Otezla as a condition for the companies’ proposed $13.4 billion merger. Commissioners Rohit Chopra and Rebecca Slaughter offered dissenting opinions, arguing a “status quo” merger analysis is not enough to address all the potential harms of the deal.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10